Connect with us
Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

News

Celprogen Introduces 3D Printed Human Brain Organelle Model System for Studying Neurological Disease That Can Be Utilized in Generating Novel Drugs

Global banking and finance news 28

Celprogen Inc., a leader in the Stem Cell Research and Therapeutics industry for stem cell research since 2002, today announced that they have successfully finished printing 3D Brains from brain stem cells for studying neurological disease stages. The poster on this work will be presented at the Annual Neuroscience meeting in San Diego, Nov 3rd 2018. The 3D printed human brain was utilized for studying “The role of Microglia activation and deactivation in neurological diseases.” Celprogen has been able to identify and characterize 11 lead compounds that are potential drug candidates for Alzheimers, Parkinsons and Glioblastoma patients.

The present invention relates to 3D organ printing programs at Celprogen that identifies potential future use in transplant of major organ systems. At present, Celprogen is validating the 3D human printed heart, pancreas, liver, hair follicle and brain for toxicology and drug discovery research.

About Celprogen Inc.

Celprogen Inc. is a global Stem Cell Research & Therapeutics company since 2002 , which is developing a proprietary portfolio of unique therapeutics products and life science research tools that includes genetic engineering technologies, stem cell technologies for regenerative medicine, as well as bio-engineering products for tissue & organ transplants. Headquartered in Torrance, California, Celprogen is committed to the research, development, and manufacture of quality Stem Cell, Cancer Stem Cell and Primary Cell Culture products to serve our global community. Additional information about Celprogen is available at https://www.celprogen.com.

Celprogen Inc.
Jay Sharma, 310 542 8822
info@celprogen.com
www.celprogen.com

Related Topics:
Advertisement

Recent Post

Global Banking & Finance Review® is a leading financial portal and Print Magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management. Copyright © 2010-2021 GBAF Publications Ltd - All Rights Reserved.